Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05853367
Other study ID # 0472-001
Secondary ID MK-0472-001
Status Recruiting
Phase Phase 1
First received
Last updated
Start date July 6, 2023
Est. completion date February 12, 2028

Study information

Verified date June 2024
Source Merck Sharp & Dohme LLC
Contact Toll Free Number
Phone 1-888-577-8839
Email Trialsites@merck.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy, safety, and tolerability of MK-0472 administered as monotherapy and in combination with pembrolizumab (MK-3475) or MK-1084 in participants with histologically or cytologically confirmed diagnosis of advanced/metastatic solid tumors.


Recruitment information / eligibility

Status Recruiting
Enrollment 178
Est. completion date February 12, 2028
Est. primary completion date February 12, 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: The main inclusion criteria include but are not limited to the following: - Histologically or cytologically confirmed advanced/metastatic solid tumor by pathology report with oncogenic receptor tyrosine kinase (RTK) pathway alterations confirmed by a historical report or local testing and have received, or been intolerant to, all available treatment known to confer clinical benefit - Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to randomization - Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening - Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on stable (>4 weeks) antiretroviral therapy (ART) Exclusion Criteria: The main exclusion criteria include but are not limited to the following: - Has not recovered to common terminology criteria for adverse events (CTCAE) Grade 1 or better from any adverse events that were due to cancer therapeutics administered more than 4 weeks earlier. Participants receiving ongoing replacement hormone therapy for endocrine immune-related AEs will not be excluded from participation in this study - Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years - History of hyperparathyroidism or hypercalcemia - Has one or more of the following ophthalmological findings/conditions: a) Intraocular pressure >21 mm Hg and/or any diagnosis of glaucoma b) Diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion and c) Diagnosis of retinal degenerative disease - Has clinically significant cardiovascular disease - Bullous exfoliative skin disorders of any grade - Known hypersensitivity to MK-0472, MK-1084, or pembrolizumab, or any of their excipients - Received therapy with a proton-pump inhibitor or an H2 histamine blocker receptor antagonist within 7 days before the first scheduled day of study dosing - Has discontinued prior therapy with an anti-programmed cell death-1 (PD-1), anti-programmed death-ligand 1 (PD-L1), or anti-programmed death-ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor due to an adverse event - Received prior systemic anticancer therapy including investigational agents within 4 weeks before first dose - Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention - Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration - Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study medication - Has known additional malignancy that is progressing or has required active treatment within the past 2 years - Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study intervention - Has active autoimmune disease that has required systemic treatment in the past 2 years except replacement therapy - Has history of pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease - Has active infection requiring systemic therapy - Has history of allogeneic tissue/solid organ transplant - Have not adequately recovered from major surgery or have ongoing surgical complications

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
MK-0472
Oral Administration
Biological:
Pembrolizumab
IV infusion
Drug:
MK-1084
Oral Administration

Locations

Country Name City State
Canada Centre Hospitalier de l'Université de Montréal-Unit for Innovative Therapies ( Site 0100) Montréal Quebec
Canada Princess Margaret Cancer Centre ( Site 0101) Toronto Ontario
Switzerland Ospedale Regionale Bellinzona e Valli ( Site 0200) Bellinzona Ticino
Switzerland Hôpitaux Universitaires de Genève (HUG) ( Site 0202) Genève Geneve
Switzerland Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 0201) st.Gallen Sankt Gallen
United States Northwestern Memorial Hospital ( Site 0002) Chicago Illinois
United States John Theurer Cancer Center at Hackensack University Medical Center ( Site 0001) Hackensack New Jersey

Sponsors (1)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC

Countries where clinical trial is conducted

United States,  Canada,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants Who Experience a Dose Limiting Toxicity (DLT) as Assessed Using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 DLT will be defined as any drug-related AE observed during the DLT evaluation period (e.g. Cycle 1) that results in a change to a given dose or a delay in initiating the next cycle. At the end of Cycle 1 (each cycle is 21 days)
Primary Number of Participants Who Experience One or More Adverse Events (AEs) An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience one or more AE's will be reported. Up to approximately 56 months
Primary Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE) An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinue study treatment due to an AE will be reported. Up to approximately 56 months
Secondary Area Under the Concentration Time-curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of MK-0472 Blood samples will be collected at specified intervals for the determination of AUC0-t. AUC0-t is defined as the area under concentration-time curve from 0 to last quantifiable concentration. Cycle 1 Day 1; Cycle 2 Day 1: Predose and 1, 2, 4, and 8 hours postdose; Cycles 1, 2: Days 2, 15: Predose (Each cycle length = 21 days)
Secondary Lowest Plasma Concentration (Ctrough) of MK-0472 Blood samples will be collected at specified intervals for the determination of Ctrough. Ctrough is defined as the lowest concentration of MK-0472 reached before the next dose is administered. Cycles 2-6, and every third cycle up to Cycle 81: Day 1: Predose (Each cycle length = 21 days)
Secondary Maximum Serum Concentration (Cmax) of MK-0472 Blood samples will be collected at specified intervals for the determination of Cmax. Cmax is defined as the maximum concentration of MK-0472 reached. Cycle 1 Day 1; Cycle 2 Day 1: 1, 2, 4, and 8 hours postdose (Each cycle length = 21 days)
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04972981 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Phase 1
Completed NCT05086822 - A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors Phase 1
Completed NCT03260322 - A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors Phase 1
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Recruiting NCT06040541 - Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors Phase 1
Recruiting NCT05862831 - Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors Phase 1/Phase 2
Recruiting NCT03641794 - Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers Phase 1
Terminated NCT03665129 - IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors Phase 1
Not yet recruiting NCT06413680 - A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies Phase 1/Phase 2
Recruiting NCT05914116 - A Study of DB-1311 in Advanced/Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT01693562 - A Phase 1/2 Study to Evaluate MEDI4736 Phase 1/Phase 2
Recruiting NCT04387916 - A Study of KC1036 in Patients With Advanced Solid Tumors Phase 1
Completed NCT04095273 - Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug Phase 1
Not yet recruiting NCT03692520 - Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors Phase 1
Completed NCT02997176 - An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) Phase 1
Recruiting NCT04446260 - A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors Phase 1
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT02253992 - An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Phase 1/Phase 2
Recruiting NCT06076291 - An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors Phase 1
Completed NCT03545971 - A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors. Phase 1